Carlo Pozzilli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5439692/publications.pdf

Version: 2024-02-01

322 papers	18,320 citations	10956 71 h-index	18606 119 g-index
326 all docs	326 docs citations	326 times ranked	13623 citing authors

#	Article	IF	Citations
1	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	1.4	13
2	Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?. Biomedicines, 2022, 10, 231.	1.4	4
3	No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis. Neurology and Therapy, 2022, 11, 471-479.	1.4	2
4	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	1.4	3
5	Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability. European Journal of Neurology, 2022, 29, 2036-2046.	1.7	6
6	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636.	1.5	7
7	Italian translation and validation of fatigue symptoms and impacts questionnaire in relapsing multiple sclerosis (FSIQ-RMS). Neurological Sciences, 2022, 43, 4925-4932.	0.9	4
8	Shift of multiple sclerosis onset towards older age. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1137-1139.	0.9	12
9	Early use of high-efficacy diseaseâ€‘modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of Neurology, 2022, 269, 5382-5394.	1.8	32
10	Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study. Neurology and Therapy, 2022, 11, 1193-1208.	1.4	17
11	Long-term follow-up (up to 11Âyears) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. Neurological Sciences, 2022, 43, 6415-6423.	0.9	10
12	Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 539-548.	1.4	13
13	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. Multiple Sclerosis Journal, 2021, 27, 479-482.	1.4	7
14	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	1.7	6
15	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438.	1.4	19
16	Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110112.	1.5	0
17	Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. Journal of Neurology, 2021, 268, 2238-2245.	1.8	15
18	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	1.5	48

#	Article	IF	Citations
19	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	2.8	370
20	Longâ€Term Safety and Efficacy of Eculizumab in Aquaporinâ€4 <scp>IgGâ€Positive NMOSD</scp>. Annals of Neurology, 2021, 89, 1088-1098.	2.8	55
21	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543.	1.8	4
22	Long-term fingolimod treatment in two pediatric patients with multiple sclerosis. Neurological Sciences, 2021, 42, 29-36.	0.9	1
23	Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients. Frontiers in Neurology, 2021, 12, 632917.	1.1	3
24	Scoring the 10â€year risk of ambulatory disability in multiple sclerosis: the RoAD score. European Journal of Neurology, 2021, 28, 2533-2542.	1.7	16
25	Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Multiple Sclerosis and Related Disorders, 2021, 49, 102717.	0.9	4
26	Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis. Journal of Neurology, 2021, 268, 4834-4845.	1.8	16
27	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. JAMA Neurology, 2021, 78, 558.	4.5	132
28	A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis. Journal of Neurology, 2021, 268, 4698-4706.	1.8	11
29	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2021, 10, 803-818.	1.4	2
30	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	4.5	26
31	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	1.7	86
32	Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	27
33	A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis. American Journal of Neuroradiology, 2021, 42, 1927-1933.	1.2	9
34	Real world experience with Cladribine at S.Andrea Hospital of Rome. Journal of the Neurological Sciences, 2021, 429, 118113.	0.3	3
35	Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases. Frontiers in Neurology, 2021, 12, 765954.	1.1	42
36	Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients. Journal of the Neurological Sciences, 2021, 429, 117749.	0.3	0

#	Article	IF	Citations
37	Efficacy of alemtuzumab over 6â€‰years in relapsingâ€“remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis Journal, 2020, 26, 1719-1728.	1.4	13
38	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	1.7	20
39	Cognitive fatigability is a quantifiable distinct phenomenon in multiple sclerosis. Journal of Neuropsychology, 2020, 14, 370-383.	0.6	11
40	Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial. Neurotherapeutics, 2020, 17, 704-709.	2.1	5
41	Cesarean section in women with MS: A choice or a need?. Multiple Sclerosis and Related Disorders, 2020, 38, 101867.	0.9	3
42	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	4.9	64
43	Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. CNS Drugs, 2020, 34, 973-988.	2.7	37
44	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	3.7	53
45	Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19. Neurological Sciences, 2020, 42, 2903-2910.	0.9	8
46	Multi-scale resting state functional reorganization in response to multiple sclerosis damage. Neuroradiology, 2020, 62, 693-704.	1.1	13
47	A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 529.	1.1	11
48	Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 271-277.	0.9	29
49	Multiple Sclerosis Treatment and Melanoma Development. International Journal of Molecular Sciences, 2020, 21, 2950.	1.8	15
50	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurological Sciences, 2020, 41, 2843-2851.	0.9	7
51	Predicting the profile of increasing disability in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1306-1315.	1.4	24
52	Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology, 2019, 93, e733-e746.	1.5	21
53	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Frontiers in Neurology, 2019, 10, 695.	1.1	5
54	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e591.	3.1	9

#	Article	IF	Citations
55	The influence of physiotherapy intervention on patients with multiple sclerosisâ€“related spasticity treated with nabiximols (THC:CBD oromucosal spray). PLoS ONE, 2019, 14, e0219670.	1.1	7
56	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	1.8	1
57	Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 417-429.	1.4	2
58	Advances in spinal cord imaging in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984059.	1.5	69
59	Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 153.	1.1	13
60	Different regimen of natalizumab treatment in multiple sclerosis patients: A real world study in Italy. Journal of the Neurological Sciences, 2019, 405, 338-339.	0.3	1
61	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.5	88
62	Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online. Multiple Sclerosis and Related Disorders, 2019, 27, 239-246.	0.9	9
63	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	1.8	20
64	Balance worsening associated with nabiximols in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 113-117.	1.4	14
65	The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis. Neuroepidemiology, 2018, 50, 105-110.	1.1	4
66	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.5	102
67	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.5	74
68	Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. European Journal of Neurology, 2018, 25, 739-746.	1.7	12
69	Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis. Radiology, 2018, 287, 267-275.	3.6	25
70	PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL) Tj ETQq0 0 0 rgBT /Over	0.1	1
71	Relation between functional connectivity and disability in multiple sclerosis: a non-linear model. Journal of Neurology, 2018, 265, 2881-2892.	1.8	21
72	Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641880324.	1.5	16

#	Article	IF	Citations
73	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	1.5	26
74	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. Journal of Neurology, 2018, 265, 2684-2687.	1.8	35
75	044â€…Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A18.2-A19.	0.9	0
76	Abortion induces reactivation of inflammation in relapsing-remitting multipleÂsclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1272-1278.	0.9	10
77	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. CNS Drugs, 2018, 32, 963-970.	2.7	35
78	Fingolimod vs dimethyl fumarate in multiple sclerosis. Neurology, 2018, 91, e153-e161.	1.5	35
79	054â€…Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A22.2-A22.	0.9	0
80	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	1.4	126
81	Survey of diagnostic and treatment practices for multiple sclerosis in Europe. European Journal of Neurology, 2017, 24, 516-522.	1.7	34
82	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	2.8	34
83	Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial. CNS Drugs, 2017, 31, 161-168.	2.7	23
84	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	1.8	44
85	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. Multiple Sclerosis and Related Disorders, 2017, 17, 154-171.	0.9	4
86	Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Viral Immunology, 2017, 30, 622-626.	0.6	1
87	Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. Neuroepidemiology, 2017, 48, 171-178.	1.1	6
88	Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurological Sciences, 2017, 38, 1841-1848.	0.9	14
89	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858.	0.9	30
90	Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	8

#	Article	IF	Citations
91	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. Journal of the Neurological Sciences, 2017, 379, 236-240.	0.3	12
92	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurological Sciences, 2017, 38, 53-59.	0.9	25
93	Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features. Multiple Sclerosis Journal, 2017, 23, 546-555.	1.4	34
94	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naÃ¯ve patients with multiple sclerosis. Journal of Neurology, 2017, 264, 284-294.	1.8	44
95	PO152â€…Alemtuzumab efficacy in patients with relapse after course 1. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A53.1-A53.	0.9	0
96	[TecfideraÂ® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]. Farmeconomia E Percorsi Terapeutici, 2017, 18, .	0.2	0
97	Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. Multiple Sclerosis Journal, 2016, 22, 944-954.	1.4	21
98	A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. Neurology, 2016, 86, 2094-2099.	1.5	79
99	Extratemporal herpes encephalitis during natalizumab treatment: A case report. Multiple Sclerosis and Related Disorders, 2016, 10, 134-136.	0.9	7
100	Tpâ€“Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. International Journal of Cardiology, 2016, 221, 881-885.	0.8	2
101	Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis. Journal of the Neurological Sciences, 2016, 370, 211-213.	0.3	13
102	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
103	The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence. Human Brain Mapping, 2016, 37, 2431-2445.	1.9	29
104	A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta. Multiple Sclerosis and Related Disorders, 2016, 8, 99-106.	0.9	19
105	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
106	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon Î²1b therapy in relapsingâ€“remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173.	1.4	24
107	Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2016, 364, 145-147.	0.3	39
108	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749.	1.4	32

#	Article	IF	Citations
109	Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. Journal of Neurology, 2016, 263, 751-759.	1.8	35
110	Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program. Radiology, 2016, 280, 202-211.	3.6	48
111	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS ONE, 2016, 11, e0157721.	1.1	5
112	Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurology, 2015, 15, 174.	0.8	72
113	Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 236-238.	0.9	8
114	Impaired Functional Connectivity Unmasked by Simple Repetitive Motor Task in Early Relapsing-Remitting Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2015, 29, 557-565.	1.4	9
115	A Low-Cost Cognitive Rehabilitation With a Commercial Video Game Improves Sustained Attention and Executive Functions in Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2015, 29, 453-461.	1.4	60
116	Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1291-1297.	1.4	41
117	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Multiple Sclerosis Journal, 2015, 21, 1713-1722.	1.4	23
118	Far transfer effect associated with video game balance training in multiple sclerosis: from balance to cognition?. Journal of Neurology, 2015, 262, 774-776.	1.8	13
119	Functional connectivity changes and their relationship with clinical disability and white matter integrity in patients with relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1681-1692.	1.4	43
120	Oral contraceptives combined with interferon Î² in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e120.	3.1	64
121	Investigating the phenomenon of â€œcognitive-motor interferenceâ€•in multiple sclerosis by means of dual-task posturography. Gait and Posture, 2015, 41, 780-785.	0.6	38
122	Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurologica Scandinavica, 2015, 131, 336-340.	1.0	43
123	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	3.7	76
124	Coping and Multiple Sclerosis. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 121-137.	0.3	2
125	Effects of the Bacillus Calmette-GuÃ©rin (BCG) Vaccine in the Demyelinating Disease of the Central Nervous System. , 2014, , 63-80.		1
126	Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1198-1208.	0.9	130

#	Article	IF	Citations
127	Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis. Multiple Sclerosis International, 2014, 2014, 1-5.	0.4	8
128	Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 566-576.	1.4	45
129	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	0.9	66
130	Mood and coping in clinically isolated syndrome and multiple sclerosis. Acta Neurologica Scandinavica, 2014, 129, 374-381.	1.0	22
131	From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. European Neurology, 2014, 71, 233-241.	0.6	4
132	Overview of MS Spasticity. European Neurology, 2014, 71, 1-3.	0.6	16
133	The MoSt Projectâ€“â€“More Steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. Journal of Neurology, 2014, 261, 526-532.	1.8	5
134	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	0.9	30
135	Multiple Sclerosis: Altered Thalamic Resting-State Functional Connectivity and Its Effect on Cognitive Function. Radiology, 2014, 271, 814-821.	3.6	116
136	Effects of Bacille Calmette-GuÃ©rin after the first demyelinating event in the CNS. Neurology, 2014, 82, 41-48.	1.5	128
137	Multiple Sclerosis: Changes in Microarchitecture of White Matter Tracts after Training with a Video Game Balance Board. Radiology, 2014, 273, 529-538.	3.6	88
138	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.5	227
139	Balance deficit with opened or closed eyes reveals involvement of different structures of the central nervous system in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 81-90.	1.4	38
140	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	0.8	27
141	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurology, 2014, 14, 65.	0.8	47
142	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.5	2,344
143	Interferon-beta-1a treatment has a positive effect on quality of life of relapsingâ€“remitting multiple sclerosis: Results from a longitudinal study. Journal of the Neurological Sciences, 2014, 337, 180-185.	0.3	9
144	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological Sciences, 2013, 34, 2085-2093.	0.9	46

#	Article	IF	Citations
145	Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Review of Neurotherapeutics, 2013, 13, 49-54.	1.4	83
146	The Diagnostic Accuracy of Static Posturography in Predicting Accidental Falls in People With Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2013, 27, 45-52.	1.4	123
147	Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Multiple Sclerosis Journal, 2013, 19, 411-417.	1.4	23
148	Home-Based Balance Training Using the Wii Balance Board. Neurorehabilitation and Neural Repair, 2013, 27, 516-525.	1.4	151
149	A mechanism-based classification of pain in multiple sclerosis. Journal of Neurology, 2013, 260, 351-367.	1.8	157
150	Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacological Research, 2013, 67, 1-9.	3.1	77
151	Multiple Sclerosis: White and Gray Matter Damage Associated with Balance Deficit Detected at Static Posturography. Radiology, 2013, 268, 181-189.	3.6	76
152	The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review. Multiple Sclerosis International, 2013, 2013, 1-9.	0.4	38
153	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Multiple Sclerosis Journal, 2013, 19, 1106-1112.	1.4	56
154	Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial. Clinical Rehabilitation, 2013, 27, 803-812.	1.0	38
155	Structural Brain MR Imaging Changes Associated with Obsessive-Compulsive Disorder in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2013, 34, 305-309.	1.2	19
156	What is Erythema Annulare Centrifugum? A Familial Case. European Journal of Inflammation, 2013, 11, 531-533.	0.2	2
157	Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod. Therapeutics and Clinical Risk Management, 2013, 9, 73.	0.9	15
158	Assessing the Correlation between Grey and White Matter Damage with Motor and Cognitive Impairment in Multiple Sclerosis Patients. PLoS ONE, 2013, 8, e63250.	1.1	92
159	Evidence of Impaired Brain Activity Balance after Passive Sensorimotor Stimulation in Multiple Sclerosis. PLoS ONE, 2013, 8, e65315.	1.1	14
160	Relating Brain Damage to Brain Plasticity in Patients With Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2012, 26, 581-593.	1.4	61
161	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 329-334.	1.4	77
162	MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1337-1339.	1.4	15

#	Article	IF	Citations
163	Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 64-71.	1.4	85
164	Assessing walking disability in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 914-924.	1.4	236
165	Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. Journal of the Neurological Sciences, 2012, 323, 104-112.	0.3	47
166	Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. Journal of Neurology, 2012, 259, 2319-2328.	1.8	28
167	Determinants of the severity of comorbid migraine in multiple sclerosis. Neurological Sciences, 2012, 33, 1345-1353.	0.9	15
168	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	0.8	82
169	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	0.8	78
170	The Impact of Interferon Beta and Natalizumab on Comorbid Migraine in Multiple Sclerosis. Headache, 2012, 52, 1130-1135.	1.8	28
171	Pulse monthly steroids during an elective interruption of natalizumab: a postâ€marketing study. European Journal of Neurology, 2012, 19, 783-787.	1.7	43
172	The relationship between infratentorial lesions, balance deficit and accidental falls in multiple sclerosis. Journal of the Neurological Sciences, 2011, 304, 55-60.	0.3	77
173	Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis â€" Results of the BetaPlus observational cohort study. Journal of the Neurological Sciences, 2011, 307, 120-126.	0.3	59
174	Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis: a cross-sectional and longitudinal fMRI study. Multiple Sclerosis Journal, 2011, 17, 1177-1184.	1.4	10
175	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex‹sup›Â®‹/sup›), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology, 2011, 18, 1122-1131.	1.7	364
176	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	4.9	247
177	Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurological Sciences, 2011, 31, 303-307.	0.9	23
178	The use of ID migraineâ„¢ questionnaire in patients with multiple sclerosis. Neurological Sciences, 2011, 32, 269-273.	0.9	10
179	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Groupâ€"Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358.	0.9	17
180	Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?. BMC Neurology, 2011, 11, 26.	0.8	19

#	Article	IF	Citations
181	Structural and functional bases for individual differences in motor learning. Human Brain Mapping, 2011, 32, 494-508.	1.9	136
182	Preservation of motor skill learning in patients with multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 103-115.	1.4	69
183	Observations during an elective interruption of natalizumab treatment: a post-marketing study. Multiple Sclerosis Journal, 2011, 17, 372-375.	1.4	33
184	Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1432-1440.	1.4	22
185	Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470.	0.9	42
186	Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets. Therapeutics and Clinical Risk Management, 2010, 6, 391.	0.9	6
187	Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Voxelwise Regional Investigation of White and Gray Matter. Radiology, 2010, 254, 227-234.	3.6	74
188	Gray- and White-Matter Changes 1 Year after First Clinical Episode of Multiple Sclerosis: MR Imaging. Radiology, 2010, 257, 448-454.	3.6	74
189	Visuo-proprioceptive training reduces risk of falls in patients with multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 491-499.	1.4	60
190	Treating multiple sclerosis with fingolimod or intramuscular interferon. Expert Opinion on Pharmacotherapy, 2010, 11, 1957-1960.	0.9	4
191	Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study. BMC Neurology, 2009, 9, 54.	0.8	25
192	Power spectrum analysis contribution to the detection of cardiovascular dysautonomia in multiple sclerosis. Acta Neurologica Scandinavica, 2009, 93, 241-245.	1.0	37
193	Natalizumab treatment in pediatric multiple sclerosis: A case report. European Journal of Paediatric Neurology, 2009, 13, 67-71.	0.7	59
194	Realâ€life impact of early interferonÎ² therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	2.8	132
195	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	0.9	68
196	The pharmacovigilance program on natalizumab in Italy: 2Âyears of experience. Neurological Sciences, 2009, 30, 163-165.	0.9	16
197	Intracortical excitability in patients with relapsingâ€“remitting and secondary progressive multiple sclerosis. Journal of Neurology, 2009, 256, 933-938.	1.8	63
198	Oneâ€year MRI scan predicts clinical response to interferon beta in multiple sclerosis. European Journal of Neurology, 2009, 16, 1202-1209.	1.7	122

#	Article	IF	Citations
199	Cannabinoidâ€induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis. European Journal of Pain, 2009, 13, 472-477.	1.4	44
200	Sex hormones, brain damage and clinical course of Multiple Sclerosis. Journal of the Neurological Sciences, 2009, 286, 35-39.	0.3	52
201	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. Journal of the Neurological Sciences, 2009, 286, 109-113.	0.3	23
202	MRI for monitoring response to preventive treatment in multiple sclerosis. Expert Review of Neurotherapeutics, 2009, 9, 305-307.	1.4	1
203	Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis. Clinical Neuropharmacology, 2009, 32, 41-47.	0.2	87
204	Primary headache and multiple sclerosis: preliminary results of a prospective study. Neurological Sciences, 2008, 29, 146-148.	0.9	43
205	Clinical markers of therapeutic response to disease modifying drugs. Neurological Sciences, 2008, 29, 211-213.	0.9	14
206	Alexithymia in multiple sclerosis: relationship with fatigue and depression. Acta Neurologica Scandinavica, 2008, 118, 18-23.	1.0	48
207	Emerging oral drugs for multiple sclerosis. Expert Opinion on Emerging Drugs, 2008, 13, 465-477.	1.0	17
208	Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period. Clinical Neuropharmacology, 2008, 31, 167-172.	0.2	25
209	An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 343-347.	1.4	7
210	Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 783-791.	1.4	113
211	Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Multiple Sclerosis Journal, 2007, 13, 1086-1094.	1.4	50
212	Diffusion-Weighted Imaging Tractography-Based Parcellation of the Human Lateral Premotor Cortex Identifies Dorsal and Ventral Subregions with Anatomical and Functional Specializations. Journal of Neuroscience, 2007, 27, 10259-10269.	1.7	303
213	Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clinical Rehabilitation, 2007, 21, 331-337.	1.0	96
214	Effect of corpus callosum damage on ipsilateral motor activation in patients with multiple sclerosis: A functional and anatomical study. Human Brain Mapping, 2007, 28, 636-644.	1.9	112
215	Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. European Journal of Neurology, 2007, 14, 1281-1287.	1.7	20
216	The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2007, 192, 174-183.	1.1	74

#	Article	IF	Citations
217	Real time PCR for detection of Chlamydophila pneumoniae in peripheral blood mononuclear cells of patients with multiple sclerosis. Journal of Neurology, 2007, 254, 1293-1295.	1.8	6
218	Treatment of early-onset multiple sclerosis with intramuscular interferonÎ²-1a: long-term results. Neurological Sciences, 2007, 28, 127-132.	0.9	57
219	Sex hormones: a role in the control of multiple sclerosis?. Expert Opinion on Pharmacotherapy, 2006, 7, 857-868.	0.9	22
220	Brain reorganization during attention and memory tasks in multiple sclerosis: Insights from functional MRI studies. Journal of the Neurological Sciences, 2006, 245, 93-98.	0.3	54
221	Predictors of longâ€“term clinical response to interferon beta therapy in relapsing multiple sclerosis. Journal of Neurology, 2006, 253, 287-293.	1.8	113
222	Treatment of multiple sclerosis-related fatigue: pharmacological and non-pharmacological approaches. Neurological Sciences, 2006, 27, s297-s299.	0.9	2
223	Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. European Journal of Neurology, 2005, 12, 817-827.	1.7	226
224	The distribution of magnetic resonance imaging response to interferonÎ²â€“1b in multiple sclerosis. Journal of Neurology, 2005, 252, 1455-1458.	1.8	23
225	Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Multiple Sclerosis Journal, 2005, 11, 441-446.	1.4	78
226	A longitudinal fMRI study on motor activity in patients with multiple sclerosis. Brain, 2005, 128, 2146-2153.	3.7	87
227	Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Multiple Sclerosis Journal, 2005, 11, 390-394.	1.4	22
228	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis Journal, 2005, 11, 420-424.	1.4	99
229	MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Multiple Sclerosis Journal, 2005, 11, 433-440.	1.4	47
230	Title is missing!. Journal of the Neurological Sciences, 2005, 234, 119-120.	0.3	1
231	Relationship between emotional distress in caregivers and health status in persons with multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 442-446.	1.4	52
232	The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. Journal of Neurology, 2004, 251, 432-439.	1.8	68
233	Testosterone amplifies excitotoxic damage of cultured oligodendrocytes. Journal of Neurochemistry, 2004, 88, 1179-1185.	2.1	56
234	Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences, 2004, 218, 103-108.	0.3	146

#	Article	IF	Citations
235	Corticosteroids treatment. Journal of the Neurological Sciences, 2004, 223, 47-51.	0.3	43
236	Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. Journal of the Neurological Sciences, 2004, 222, 99-104.	0.3	122
237	Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2004, 224, 23-27.	0.3	24
238	Corrigendum to â€œComputer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trialâ€•[J. Neurol. Sci. 222 (2004) 99â€“104]. Journal of the Neurological Sciences, 2004, 224, 113.	0.3	1
239	fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. NeuroImage, 2004, 21, 858-867.	2.1	285
240	Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet, The, 2004, 364, 1149-1156.	6.3	181
241	The effect of Bacille Calmette-GuÃ©rin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. Journal of Neurology, 2003, 250, 247-248.	1.8	59
242	Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study. Neurological Sciences, 2003, 24, 340-345.	0.9	9
243	â€˜Gender gapâ€™ in multiple sclerosis: magnetic resonance imaging evidence. European Journal of Neurology, 2003, 10, 95-97.	1.7	126
244	Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. Journal of the Neurological Sciences, 2003, 215, 3-8.	0.3	61
245	Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Multiple Sclerosis Journal, 2003, 9, 342-348.	1.4	39
246	Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 302-306.	1.4	58
247	Pharmacological methods to overcome IFN-Î² antibody formation in the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs, 2003, 12, 1153-1163.	1.9	5
248	Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain, 2002, 125, 1607-1615.	3.7	171
249	MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Multiple Sclerosis Journal, 2002, 8, 119-123.	1.4	49
250	Prospective study of multiple sclerosis with early onset. Multiple Sclerosis Journal, 2002, 8, 115-118.	1.4	134
251	Contribution of Corticospinal Tract Damage to Cortical Motor Reorganization after a Single Clinical Attack of Multiple Sclerosis. NeuroImage, 2002, 17, 1837-1843.	2.1	107
252	Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurologica Scandinavica, 2002, 106, 109-112.	1.0	73

#	Article	IF	Citations
253	A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. European Journal of Neurology, 2002, 9, 645-655.	1.7	65
254	A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. Magnetic Resonance Imaging, 2002, 20, 383-388.	1.0	82
255	Monthly corticosteroids decrease neutralizing antibodies to IFNÎ²1b: a randomized trial in multiple sclerosis. Journal of Neurology, 2002, 249, 50-56.	1.8	83
256	Epidemiology and current treatment of multiple sclerosis in Europe today. Journal of Rehabilitation Research and Development, 2002, 39, 175-85.	1.6	12
257	Patterns of Cognitive Impairment in Secondary Progressive Stable Phase of Multiple Sclerosis: Correlations with MRI Findings. European Neurology, 2001, 45, 11-18.	0.6	50
258	T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain, 2001, 124, 1396-1402.	3.7	85
259	Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. Multiple Sclerosis Journal, 2001, 7, 27-31.	1.4	2
260	Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Multiple Sclerosis Journal, 2001, 7, 354-358.	1.4	17
261	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Medicine, 2000, 6, 1176-1182.	15.2	506
262	Global immune disregulation in multiple sclerosis: from the adaptive response to the innate immunity. Journal of Neuroimmunology, 2000, 107, 216-219.	1.1	7
263	Brain atrophy in relapsing-remitting multiple sclerosis: relationship with â€˜black holesâ€™, disease duration and clinical disability. Journal of the Neurological Sciences, 2000, 174, 85-91.	0.3	110
264	Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study. Multiple Sclerosis Journal, 2000, 6, 43-49.	1.4	1
265	Antinuclear antibodies and response to IFNÎ²-1a therapy in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 137-139.	1.4	0
266	Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. European Journal of Neurology, 1999, 6, 455-459.	1.7	59
267	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. Journal of Neurology, 1999, 246, 97-106.	1.8	9
268	Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon Î² 1a. Journal of Neurology, 1999, 246, 443-448.	1.8	26
269	Fatigue and magnetic resonance imaging activity in multiple sclerosis. Journal of Neurology, 1999, 246, 454-458.	1.8	104
270	T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis. Journal of Neuroimmunology, 1999, 99, 91-96.	1.1	14

#	Article	IF	Citations
271	Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. Journal of the Neurological Sciences, 1999, 168, 131-136.	0.3	61
272	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. Journal of the Neurological Sciences, 1999, 171, 130-134.	0.3	15
273	Memory and executive functions in healthy subjects and patients with multiple sclerosis: the role of PET and SPECT. Italian Journal of Neurological Sciences, 1998, 19, S403-S407.	0.1	1
274	Serum amyloid A protein is elevated in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 1998, 88, 9-12.	1.1	28
275	A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. Journal of the Neurological Sciences, 1998, 159, 94-101.	0.3	11
276	Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-Î²1a. Journal of Interferon and Cytokine Research, 1998, 18, 345-350.	0.5	67
277	MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 221-225.	1.4	31
278	Down-regulation of cell-surface CD4 co-receptor expression and modulation of experimental allergic encephalomyelitis. International Immunology, 1997, 9, 541-545.	1.8	12
279	Multiple sclerosis in childhood: clinical features of 149 cases. Multiple Sclerosis Journal, 1997, 3, 43-46.	1.4	275
280	HLA-DM polymorphisms do not associate with multiple sclerosis: an association study with analysis of myelin basic protein T cell specificity. Journal of Neuroimmunology, 1997, 77, 181-184.	1.1	13
281	The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurologica Scandinavica, 1997, 95, 201-207.	1.0	21
282	Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology, 1997, 244, 153-159.	1.8	257
283	No increase of serum autoantibodies during therapy with recombinant human interferon-Î²1a in relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica, 1997, 96, 372-374.	1.0	36
284	Functional Basis of Memory Impairment in Multiple Sclerosis: A [18F]FDG PET Study. NeuroImage, 1996, 4, 87-96.	2.1	127
285	Involvement of the limbic system in multiple sclerosis patients with depressive disorders. Biological Psychiatry, 1996, 39, 970-975.	0.7	76
286	The immune response to Mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. Journal of Neuroimmunology, 1996, 65, 143-153.	1.1	58
287	Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. Journal of Neurology, 1995, 242, 143-146.	1.8	46
288	Crossed quadrant homonymous hemianopsia in a case of multiple sclerosis. Clinical Neurology and Neurosurgery, 1995, 97, 324-327.	0.6	8

#	Article	IF	Citations
289	Progressing Neurological Deficit Secondary to Acute Ischemic Stroke. Archives of Neurology, 1995, 52, 670.	4.9	245
290	Spontaneous Middle Cerebral Artery Reperfusion in Ischemic Stroke. Stroke, 1995, 26, 430-433.	1.0	90
291	Factors Affecting Course and Survival in Alzheimer's Disease. Archives of Neurology, 1994, 51, 1213.	4.9	112
292	Antiphospholipid antibodies and cerebral artery dissection: Two frequent causes of brain ischemia in young adults. Italian Journal of Neurological Sciences, 1994, 15, 221-227.	0.1	1
293	Dynamics of the autoimmune T-cell repertoire in experimental allergic encephalomyelitis and in multiple sclerosis. Trends in Immunology, 1994, 15, 89-90.	7.5	2
294	A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year. Canadian Journal of Neurological Sciences, 1994, 21, 266-270.	0.3	50
295	Mesial temporal cortex hypoperfusion is associated with depression in subcortical stroke.. Stroke, 1994, 25, 980-985.	1.0	41
296	Psychostimulant drugs increase glucose utilization in the shell of the rat nucleus accumbens. NeuroReport, 1994, 5, 2561-2564.	0.6	46
297	Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis. European Journal of Immunology, 1993, 23, 1232-1239.	1.6	74
298	Transcranial Doppler Ultrasonography and Single Photon Emission Tomography following Cerebral Infarction. Cerebrovascular Diseases, 1993, 3, 370-374.	0.8	4
299	Lack of association between macrocytosis and multiple sclerosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1096-1096.	0.9	5
300	T-lymphocyte reactivity to the recombinant mycobacterial 65- and 70-kDa heat shock proteins in multiple sclerosis. Journal of Autoimmunity, 1992, 5, 691-702.	3.0	61
301	Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis. Journal of the Neurological Sciences, 1992, 112, 51-57.	0.3	37
302	HLA Determinants in Familial Multiple Sclerosis. Neuroepidemiology, 1992, 11, 85-89.	1.1	12
303	Structural Brain Correlates of Neurourologic Abnormalities in Multiple Sclerosis. European Neurology, 1992, 32, 228-230.	0.6	25
304	Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. Acta Neurologica Scandinavica, 1992, 86, 354-358.	1.0	49
305	Anterior Corpus Callosum Atrophy and Verbal Fluency in Multiple Sclerosis. Cortex, 1991, 27, 441-445.	1.1	86
306	Quantitative Assessment of Cerebral Blood Flow in Partial Epilepsy Using Xe-133 Inhalation and SPECT. Clinical Nuclear Medicine, 1991, 16, 898-903.	0.7	8

#	Article	IF	Citations
307	Predictive value of brain perfusion single-photon emission computed tomography in acute ischemic stroke.. Stroke, 1990, 21, 895-900.	1.0	122
308	Systemic hypertension as a treatable risk factor for cerebrovascular disease. American Journal of Cardiology, 1989, 63, C19-C21.	0.7	2
309	Influence of nimodipine on cerebral blood flow in human cerebral ischaemia. Journal of Neurology, 1989, 236, 199-202.	1.8	33
310	Facts and Trends in Cerebral Blood Flow and Metabolism: Synopsis of Brain '89. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 573-578.	2.4	7
311	Positron CT imaging of an impending stroke. Neuroradiology, 1988, 30, 276-279.	1.1	9
312	Remote Effects of Subcortical Cerebrovascular Lesions: A SPECT Cerebral Perfusion Study. Journal of Cerebral Blood Flow and Metabolism, 1988, 8, 560-567.	2.4	55
313	Simplified, Noninvasive PET Measurement of Blood-Brain Barrier Permeability. Journal of Computer Assisted Tomography, 1987, 11, 390-397.	0.5	70
314	Remote Effects of Caudate Hemorrhage: A Clinical and Functional Study. Cortex, 1987, 23, 341-349.	1.1	40
315	Sequential Computed Tomography and ¹²³I-HIPDM Scans in Multiple Sclerosis with Large Plaque. European Neurology, 1987, 27, 88-91.	0.6	5
316	Haemodynamics and oxygen metabolism in patients after reversible ischaemic attack or minor ischaemic stroke assessed with positron emission tomography. Neuroradiology, 1987, 29, 416-421.	1.1	14
317	Positron Emission Tomography in Minor Ischemic Stroke Using Oxygen-15 Steady-State Technique. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 137-142.	2.4	11
318	Imaging of leukocytic infiltration in human cerebral infarcts.. Stroke, 1985, 16, 251-255.	1.0	120
319	Peripheral white blood cell count in cerebral ischemic infarction. Acta Neurologica Scandinavica, 1985, 71, 396-400.	1.0	71
320	TRACKING OF INDIUM-111-OXINE LABELLED LYMPHOCYTES IN AUTOIMMUNE THYROID DISEASE. Clinical Endocrinology, 1983, 19, 111-116.	1.2	28
321	Measurement of CBF and CMRO2 using the continuous inhalation of C15O2 and 15O2. Journal of the Neurological Sciences, 1981, 50, 381-389.	0.3	57
322	CMRO₂ and CBF by the Oxygen-15 Inhalation Technique. European Neurology, 1981, 20, 285-290.	0.6	104